Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $66.6667.

RVPH has been the subject of several recent research reports. D. Boral Capital cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st. Maxim Group cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. Finally, Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC purchased a new position in Reviva Pharmaceuticals in the 2nd quarter valued at approximately $1,026,000. Millennium Management LLC raised its holdings in shares of Reviva Pharmaceuticals by 15.0% in the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after purchasing an additional 223,178 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Reviva Pharmaceuticals by 87.6% in the 4th quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock valued at $293,000 after purchasing an additional 489,711 shares in the last quarter. State Street Corp raised its holdings in shares of Reviva Pharmaceuticals by 202.4% in the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after purchasing an additional 256,500 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in shares of Reviva Pharmaceuticals by 63.6% in the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock valued at $46,000 after purchasing an additional 63,893 shares in the last quarter. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $0.61 on Friday. The stock has a market capitalization of $8.00 million, a P/E ratio of -0.15 and a beta of 0.56. The company has a 50 day moving average price of $0.68 and a 200 day moving average price of $4.07. Reviva Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $17.20.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.10). Research analysts forecast that Reviva Pharmaceuticals will post -2.96 earnings per share for the current fiscal year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.